Fumagillin class inhibitors of methionine aminopeptidase-2

Drugs of the Future

Volumn 30, Issue 5, 2005, Pages 497-508

  Bernier, Sylvie G ^a   Westlin, William F ^a   Hannig, Gerhard ^a  

^a Praecis Pharmaceuticals Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC ANTIBIOTIC; CARBOPLATIN; CISPLATIN; CKD 732; CYCLOSPORIN; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; METHIONYL AMINOPEPTIDASE; METHIONYL AMINOPEPTIDASE 2; PACLITAXEL; PPI 2458; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTHRITIS; CANCER THERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL GROWTH; CLINICAL TRIAL; CYTOSTASIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LUNG NON SMALL CELL CANCER; MICROSPORIDIOSIS; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; THROMBOCYTOPENIA;

EID: 22244484427     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.05.895807     Document Type: Review

References (98)

1. Folkman, J. Tumor angiogenesis: Therapeutic implications. New Engl J Med 1971, 285: 1182-6.
2. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamuru, T., Brem, H., Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990, 348: 555-7.
3. Griffith, E.G., Su, Z., Turk, B.E. et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 1997, 4: 461-71.
4. Sin, N., Meng, L., Wang, M.Q.W., Wen, J.J., Bornmann, W.G., Crews, C.M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 1997, 94: 6099-103.
5. Liu, S., Widom, J., Kemp, C.W., Crews, C.M., Clardy, J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 1998, 282: 1324-7.
6. Kusaka, M., Sudo, K., Kozai, Y., Marui, S., Fujita, T., Ingber, D., Folkman, J. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994, 69: 212-6.
7. Bernier, S.G., Lazarus, D.D., Clark, E., Doyle, B., Labenski, M.T., Thompson, C.D., Westlin, W.F., Hannig, G. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci USA 2004, 101: 10768-73.
8. Bernier, S.G., Taghizadeh, N., Thompson, C.D., Westlin, W.F., Hannig, G. Methionine aminopeptidases type I and type II are essential to control cell proliferation. J Cell Biochem 2005, in press.
9. Abe, J., Zhou, W., Taguchi, J., Kurokawa, K., Kumada, M., Takuwa, Y. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994, 54: 3407-12.
10. CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci USA 2000, 97: 12782-7.
11. WAF1/CIP1. Proc Natl Acad Sci USA 2000, 97: 6427-32.
12. Hori, A., Ikeyama, S., Sudo, K. Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells. Biochem Biophys Res Comm 1994, 204: 1067-73.
13. Arfin, S.M., Kendall, R.L., Hall, L., Weaver, L.H., Stewart, A.E., Matthews, B.W., Bradshaw, R.A. Eukaryotic methionyl aminopeptidases: Two classes of cobalt-dependent enzymes. Proc Natl Acad Sci USA 1995, 92: 7714-8.
14. Bradshaw, R.A., Yi, E. Methionine aminopeptidases and angiogenesis. Essays Biochem 2002, 38: 65-78.
15. Keeling, P.J., Doolittle, W.F. Methionine aminopeptidase-1: The MAP of the mitochondrion? TIBS 1986, 21: 285-6.
16. Datta, B., Chakrabarti, D., Roy, A.L., Gupta, N.K. Roles of a 67-kDa polypeptide in reversal of protein synthesis inhibition in heme-deficient reticulocyte lysate. Proc Natl Acad Sci USA 1988, 85: 3324-8.
17. Datta, B., Ray, M.K., Chakrabarti, D., Wylie, D.E., Gupta, N.K. Glycosylation of eukaryotic peptide chain initiation factor 2 (elF-2)-associated 67-kDa polypeptide (p67) and its possible role in the inhibition of elF-2 kinase-catalyzed phosphorylation of the elF-2 alpha-subunit. J Biol Chem 1989, 264: 20620-4.
18. Chang, T.H., Teichert, U., Smith, J.A. Molecular cloning, sequencing, deletion, and overexpression of a methionine aminopeptidase gene from Saccharomyces cerevisiae. J Biol Chem 1992, 267: 8007-11.
19. Li, X., Chang, Y.H. Amino-terminal protein processing in Saccharomyces cerevisiae is an essential function that requires two distinct methionine aminopeptidases. Proc Natl Acad Sci USA 1995, 92: 12357-61.
20. Catalane, A., Romano, M., Robuffo, I., Strizzi, L., Procopio, A. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: Role of Bcl-2 expression and telomerase activity. Am J Pathol 2001, 159: 721-31.
21. Turk, B., Griffith, E.G., Wolf, S., Biemann, K., Chang, Y.H., Liu, J.O. Selective inhibition of amino-terminal processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 1999, 6: 823-33.
22. Wang, J., Lou, P., Henkin, J. Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem 2000, 77: 465-73.
23. Wang, J., Sheppard, G.S., Lou, P. et al. Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res 2003, 63: 7861-9.
24. Griffith, E.G., Su, Z., Niwayama, S., Ramsay, C.A., Chang, Y.H., Liu, J.O. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci USA 1998, 95: 15183-8.
25. Klein, C.D., Folkers, G. Understanding the selectivity of fumagillin for the methionine aminopeptidase type II. Oncol Res 2003, 13: 513-20.
26. Lowther, W.T., Matthews, B.W. Structure and function of the methionine aminopeptidases. Biochim Biophys Acta 2000, 1477: 157-67.
27. Hanson, F.R., Eble, T.E. An antiphage agent isolated from Aspergillus sp. J Bacteriol 1949, 58: 527-9.
28. McCowen, M.C., Callender, M.E., Lawlis, J.F. Jr. Fumagillin (H-3), a new antibiotic with amebicidal properties. Science 1951, 113: 202-3.
29. Killough, J.H., Magill, G.B., Smith, R.C. The treatment of amebiasis with fumagillin. Science 1952, 115: 71-2.
30. Diesenhouse, M.C., Wilson, L.A., Corrent, G.F., Visvesvara, G.S., Grossni-Klaus, H.E., Bryan, R.T. Treatment of microsporidial keratoconjunctivitis with topical fumagillin. Am J Ophthalmol 1993, 115: 293-8.
31. Wilkins, J.H., Joshi, N., Margolis, T.P., Cevallos, V., Dawson, D.R. Microsporidial keratoconjunctivitis treated successfully with a short course of fumagillin. Eye 1994, 8: 703-4.
32. Molina, J.-M., Goguel, J., Sarfati, C. et al. Potential efficacy of fumagillin in intestinal microsporidiosis due to Enterocytozoon bieneusi in patients with HIV infection: Results of a drug screening study. AIDS 1997, 11: 1603-10.
33. Molina, J.-M., Goguel, J., Sarfati, C. et al. Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. AIDS 2000, 14: 1341-8.
34. Molina, J.-M., Tourneur, M., Sarfati, C. et al. Fumagillin treatment of intestinal microsporidiosis. New Engl J Med 2002, 346: 1963-9.
35. Han, C.K., Ahn, S.K., Choi, N.S. et al. Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP2. Bioorg Med Chem Lett 2000, 10: 39-43.
36. Chun, E., Han, C.K., Yoon, J.H., Sim, T.B., Kim, Y.-K., Lee, K.-Y. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Int J Cancer 2005, 114: 124-30.
37. Kim, J.-H., Lee, S.-K., Ki, M.-H., Choi, W.-K., Ahn, S.-K., Shin, H.-J., Hong, C.I. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732, through complexation with hydroxypropyl-β-cyclodextrin. Int J Pharmaceut 2004, 272: 79-89.
38. Kim, E.-J., Shin, W.-H. General pharmacology of CKD-732, a new anticancer agent: Effects on central nervous, cardiovascular, and respiratory system. Biol Pharm Bull 2005, 28: 217-23.
39. Castronovo, V., Belotti, D. TNP-470 (AGM-1470): Mechanisms of action and early clinical development. Eur J Cancer 1996, 32A: 2520-7.
40. Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K., Fujita, T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-dependent human breast and prostate carcinoma cell lines. Cancer Res 1993, 53: 5233-6.
41. Yamaoka, M., Yamamoto, T., Masaki, T., Ikeyama, S., Sudo, K., Fujita, T. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470). Cancer Res 1993, 53: 4262-7.
42. Muramaki, M., Miyake, H., Hara, I., Kawabata, G., Kamidono, S. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KOTCC-1 model. J Urol 2004, 172: 1485-9.
43. Teicher, B.A., Sotomayor, E.A., Huang, Z.D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992, 5: 6702-4.
44. Teicher, B.A., Holden, S.A., Ara, G., Sotomayor, E.A., Huang, Z.D., Chen, Y.N., Brem, H. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994, 57: 920-5.
45. Teicher, B.A., Holden, S.A., Ara, G., Kornbut, T., Menon, K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol 1996, 38: 169-77.
46. Peacock, D.J., Banquerigo, M.L., Brahn, E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992, 175: 1135-8.
47. De Brandt, M., Grossin, M., Weber, A.J. et al. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum 2000, 43: 2056-63.
48. Peacock, D.J., Banquerigo, M.L., Brahn, E. A novel angiogenesis inhibitor suppresses rat adjuvant arthritis. Cell Immunol 1995, 160: 174-84.
49. Oliver, S.J., Banquerigo, M.L., Brahn, E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, Taxol. Cell Immunol 1994, 157: 291-9.
50. Oliver, S.J., Cheng, T.P., Banquerigo, M.L., Brahn, E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporine: Reduction of vascular endothelial growth factor (VEGF). Cell Immunol 1995, 166: 196-206.
51. Denton, M.D., Magee, C., Melter, M., Dharnidharka, V.R., Sayegh, M.H., Briscoe, D.M. TNP-470, an angiogenesis inhibitor, attenuates the development of allograft vasculopathy. Transplantation 78: 1218-21.
52. Yoshio, Y., Miyazaki, M., Abe, K. et al. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 2004, 66: 1677-85.
53. Zhang, P., Nicholson, D.E., Bujnicki, J.M. et al. Angiogenesis inhibitors specific for methionine aminopeptidase 2 as drugs for malaria and leishmaniasis. J Biomed Sci 2002, 9: 34-40.
54. Coyle, C., Kent, M., Tanowitz, H.B., Wittner, M., Weiss, L.M. TNP-470 is an effective antimicrosporidial agent. J Infect Dis 1998, 177: 515-8.
55. Brem, H., Ehrlich, P., Tsakayannis, D.E., Folkman, J. Delay of wound healing by the angiogenesis inhibitor TNP-470. Surg Forum 1997, 48: 716.
56. Klein, S.A., Bond, S.J., Gupta, S.C., Yacoub, O.A., Anderson, G.I. Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. J Surg Res 1999, 82: 268-74.
57. Klauber, N., Rohan, R.M., Flynn, E., D'Amato, R.J. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat Med 1997, 3: 443-6.
58. Fraser, H., Dickson, S., Lunn, S. The effect of antiangiogenic agent TNP-470 on luteal establishment and function in the macaque and marmoset. IBC Angiogenesis Conference 1998, Abst.
59. Bhargava, P., Dordal, M.S., Hawkins, M.J. TNP-470. In: Angiogenesis in Health and Disease: Basic Mechanisms and Future Directions. G.M. Rubayni (Ed.). Marcel Dekker Inc: New York 2000, 387-406.
60. Kruger, E.A., Figg, W.D. TNP-470: An angiogenesis inhibitor in clinical development for cancer. Exp Opin Invest Drugs 2000, 9: 1383-96.
61. Satchi-Fainaro, R., Puder, M, Davies, J.W. et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004, 10: 255-61.
62. Satchi-Fainaro, R., Mamluk, R., Wang, L. et al. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 2005, 7: 251-61.
63. Biggar, R.J., Rabkin, C.S. The epidemiology of AIDS-related neoplasms. Hematol Clin North Am 1996, 10: 997-1010.
64. Dezube, B.J., Von Roenn, J.H., Holden-Wiltse, J. et al. Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS clinical trial group study. J Clin Oncol 1998, 16: 1444-9.
65. Bhargava, P., Marshall, J.L., Rizvi, N. et al. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999, 5: 1989-95.
66. Logothetis, C.J., Wu, K.K., Finn, L.D., Daliani, D., Figg, W., Ghaddar, H., Gutterman, J.U. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 2001, 7: 1198-203.
67. Stadler, W.M., Kuzel, T., Shapiro, C., Sosman, J., Clark, J., Vogelzang, N.J. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999, 17: 2541-5.
68. Offodile, R., Walton, T., Lee, M., Stiles, A., Nguyen, M. Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470. Tumori 1999, 85: 51-3.
69. Kudelka, A.P., Levy, T., Verschraegen, C.F. et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 1997, 3: 1501-5.
70. Herbst, R.S., Madden, T.L., Tran, H.T. et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: Evidence for activity in non-small-cell lung cancer. J Clin Oncol 2002, 20: 4440-7.
71. Figg, W.D., Pluda, J.M., Lush, R.M., Saville, M.W., Wyvill, K., Reed, E., Yarchoan, R. The pharmacokinetic profile of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 1997, 17: 91-7.
72. Moore, J.D., Dezube, B.J., Gill, P., Zhou, X.-J., Acosta, E.P., Sommadossi, J.-P. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma. Cancer Chemother Pharmacol 2000, 46: 173-9.
73. Brahn, E., Banquerigo, M.L., Schoettler, N.R., Lee, S. A new angiogenesis inhibitor, PPI-2458: Regression of collagen-induced arthritis and prevention of erosions. Arthrit Rheum 2001, 44: S271.
74. Brahn, E., Schoettler, N.R., Banquerigo, M.L., Thompson, C.D. Involution of collagen-induced arthritis with an angiogenesis inhibitor PPI-2458. Arthrit Rheum 2003, 48: S347.
75. Kanno, T., Endo, H., Takeuchi, K., Morishita, Y., Fukayama, M., Mori, S. High expression of methionine aminopeptidase type 2 in germinal center B cells and their neoplastic counterparts. Lab Invest 2002, 82: 893-901.
76. Fujioka, T., Hasegawa, M., Ogui, K., Matsushita, Y., Sato, M, Kubo, T. Antitumor effects of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma. J Urol 1996, 155: 1775-8.
77. Noren-Nystrom, U., Eriksson, M., Eriksson, B., Roos, G., Bergh, A., Holmberg, D. Antitumor activity of the angiogenesis inhibitor TNP-470 on murine lymphoma/leukemia cells in vivo and in vitro. Exp Hematol 2003, 31: 143-9.
78. Hotz, H.G., Reber, H.A., Hotz, B. et al. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J Gastrointest Surg 2001, 5: 131-8.
79. Emoto, M., Ishiguro, M., Agr, B., Iwasaki, H., Kikuchi, M., Kawarabayashi, T. Effect of angiogenesis inhibitor TNP-470 on the growth, blood flow, and microvessel density in xenografts of human uterine carcinosarcoma in nude mice. Gynecol Oncol 2003, 89: 88-94.
80. Lazarus, D.D., Bernier, S.G., Labenski, M.T. et al. Inhibition of primary tumor growth by PPI-2458, a methionine aminopeptidase-2 inhibitor: Dose and schedule responses. 2003 AACR/NCI/EORTC Intl Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst A174.
81. Hollingshead M.G., Kaur, G., Borgel, S.D. et al. In vivo efficacy of PPI-2458 (NSC 720735), a novel fumagillin analog with oral bioavailability. 2003 AACR/NCI/EORTC Intl Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst C41.
82. Tanaka, T., Konno, H., Matsuda, I., Nakamura, S., Baba, S. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 1995, 55: 836-9.
83. Sasaki, A., Alcalde, R.E., Nishiyama, A., Lim, D.D., Mese, H., Akedo, H., Matsumura, T. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res 1998, 58: 462-7.
84. Ohta, Y., Watanabe, Y., Oda, T., Hayashi, Y., Endo, Y., Tanaka, M., Sasaki, T. Inhibition of lymph node metastasis by an anti-angiogenic agent, TNP-470. Brit J Cancer 1997, 75: 512-6.
85. Shishido, T., Yasoshima, T., Denno, R., Sato, N., Hirata, K. Inhibition of liver metastasis of human gastric carcinoma by angiogenesis inhibitor TNP-470. Jpn J Cancer Res 1996, 87: 958-62.
86. Shusterman, S., Grupp, S.A., Barr, R., Carpentieri, D., Zhao, H., Maris, J.M. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 2001, 7: 977-84.
87. Shishido, T., Yasohima, T., Denno, R., Mukaiya, M., Sato, N., Hirata, K. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin. Jpn J Cancer Res 1998, 89: 963-9.
88. Tran, H.T., Blumenschein, G.R. Jr., Lu C. et al. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 2004, 54: 308-14.
89. Tsunasawa, S., Izu, Y., Miyagi, M., Kato, I. Methionine aminopeptidase from the hyperthermophilic archaeon Pyrococcus furiosus: Molecular cloning and overexpression in Escherichia coli of the gene, and characteristics of the enzyme. J Biochem 1997, 122: 843-50.
90. Li, X., Chang, Y.H. Molecular cloning of a human complementary DNA encoding an initiation factor 2-associated protein (p67). Biochim Biophys Acta 1995, 1260: 333-6.
91. Wu, S., Gupta, S., Chatterjee, N. et al. Cloning and characterization of complementary DNA encoding the eukaryotic initiation factor 2-associated 67-kDa protein (p67). J Biol Chem 1993, 268: 10796-801.
92. Pyun, H.-J., Fardis, M., Tario, J. et al. Investigation of novel fumagillin analogues as angiogenesis inhibitors. Bioorg Med Chem Lett 2004, 14: 1-94.
93. Rodeschini, V., Boiteau, J.-G., Van de Weghe, P., Tarnus, C., Eustache, J. MetAP-2 inhibitors based on the fumagillin structure, side-chain modification and ring-substituted analogues. J Org Chem 2004, 69: 357-73.
94. Balwin, J.E., Bulger, P.G., Marquez, R. Fast and efficient synthesis of novel fumagillin analogues. Tetrahedron 2002, 58: 5441-52.
95. Zhou, G., Tsai, C.W., Liu, J.O. Fumagolone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis. J Med Chem 2003, 46: 3452-4.
96. Sigg, H.P., Weber, H.P. Isolation and structure elucidation of ovalicin. Helv Chim Acta 1998, 51: 1395-408.
97. Milkowski, D.M., Weiss, R.A. TNP-470. In: Antiangiogenic Agents in Cancer Therapy. Teicher, B.A. (Ed.). Humana Press, Totowa, 1998, 385-98.
98. Lainer, D.T., Brahn, E. New antiangiogenic strategies for the treatment of proliferative synovitis. Exp Opin Invest Drugs 2005, 14: 1-17.